A5081696693- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Breast Lesions and Carcinomas
- Colorectal Cancer Treatments and Studies
- Cancer Risks and Factors
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Cardiac tumors and thrombi
- Cancer Cells and Metastasis
- Neutropenia and Cancer Infections
- Pancreatic and Hepatic Oncology Research
- Multiple Myeloma Research and Treatments
- Cancer-related Molecular Pathways
- Inflammatory Biomarkers in Disease Prognosis
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Nutrition, Genetics, and Disease
Japanese Foundation For Cancer Research
2016-2025
The Cancer Institute Hospital
2009-2024
Hyogo Prefectural Amagasaki General Medical Center
2018
Hyogo Medical University
2018
Kansai Rosai Hospital
2018
Tokyo National Hospital
2016
Cancer Institute (WIA)
2016
Breast Cancer Care
2013
Aichi Cancer Center
2013
Kurashiki Central Hospital
2009
Purpose To evaluate the association between tumor shrinkage patterns shown with magnetic resonance (MR) imaging during neoadjuvant chemotherapy (NAC) and prognosis in patients low-grade luminal breast cancer. Materials Methods This retrospective study was approved by institutional review board informed consent obtained from all subjects. The cancer defined as hormone receptor-positive human epidermal growth factor receptor 2-negative nuclear grades 1 or 2. of revealed at MR were categorized...
Although peripheral blood-based parameters (PBBPs) are reported as prognostic indicators in patients with breast cancers, their utility has not been studied human epidermal growth factor receptor 2 (HER2)-positive advanced cancer (ABC). Tumor-infiltrating lymphocytes (TILs) might be a predictive HER2-positive ABC treated pertuzumab and trastuzumab (PT) plus docetaxel. We aimed to evaluate whether PBBPs could have value combined eribulin (ERI) or nab-paclitaxel (Nab-PTX).Data from 51 included...
We present a case of metastatic breast cancer patient with cystoid macular edema (CME) occurring during treatment paclitaxel and bevacizumab. She had history neoadjuvant chemotherapy partial mastectomy plus axillary lymph node dissection for stage IIB left-breast cancer. Twenty-four months later, she was diagnosed multiple bone metastases underwent Thirty-three after the initiation chemotherapy, noticed bilateral blurred vision. The retinal thickening observed by optical coherence...
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) significantly improve progression-free survival and have become the standard therapy for estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer patients. Treatment surveillance by radiological imaging has some limitations in detection repeated biopsy genomic profiling is not clinically feasible. Serial circulating tumor DNA (ctDNA) analysis may provide insights into treatment response. Here we...
Abstract Background Existing circulating cell-free DNA (cfDNA) assays are primarily centralized, requiring specialized sample handling and transportation. Implementing a flexible, decentralized sequencing system at point of care, with minimal technical oversight, can enhance turnaround times patient access to genomic profiling. In this study, we aimed evaluate the clinical feasibility an automated cfDNA next-generation (NGS) assay for identifying actionable alterations in advanced solid...
Abstract Background Comprehensive genomic profiling (CGP) provides new opportunities for patients with advanced cancer to receive genome-matched therapies, but the availability rate of these remains low. We reviewed our CGP cases and suggested possible strategies improve current status from a clinical perspective. Methods Druggable alterations barriers accessing therapies were investigated in 653 30 various types cancers who underwent CGP. Results While as whole was 9.5%, useful some types....
782 Background: Liquid biopsy offers an alternative to tissue specimens for comprehensive genetic profiling. However, circulating tumor DNA is sometimes insufficient detect genomic alterations in pancreatic cancer (PC). The detection rate of KRAS mutations was reportedly increased PC with liver metastasis. In contrast, the predictive value CA19-9 levels, timing liquid biopsy, or type detecting remains unclear. We investigated whether these factors could be PC. Methods: From September 2021...
e12589 Background: High-grade fevers exceeding 40°C after administration of carboplatin and paclitaxel have occasionally been observed in early triple-negative breast cancer (TNBC) patients who are receiving neoadjuvant therapy based on KEYNOTE-522 trial. Methods: We retrospectively reviewed 102 TNBC initiated KEYNOTE-522-based at our institution between October 2022 2024. assessed the incidence, timing, clinical course occurring within 24 hours plus paclitaxel, with or without...
11144 Background: Cancer types in Adolescents and Young Adults (AYA) vary by age. Since many AYA cancers are classified as rare, patients continue to face limited therapeutic options. This study evaluates the utility of comprehensive genomic profiling (CGP) genome-matched therapies for cancer patients, considering age-specific variations using a nationwide database. Methods: We analyzed data from 2,325 (aged 15–39) who underwent CGP between 2019 2023. The landscape treatment status were...
Abstract Cancer genomic profile (CGP) testing, which is covered by the national health insurance system in Japan, has been introduced as a routine clinical practice. However, effects of CGP testing on prognoses remain unclear. Drug accessibility rates and after were retrospectively investigated 713 patients who underwent examined our molecular tumor board between November 2019 October 2022,. Overall survival (OS) was using log‐rank test Kaplan–Meier method. The median age (326 males 387...
Pulmonary tumor thrombotic microangiopathy (PTTM) is rare, cancer-related pulmonary complication leading to hypoxia, hypertension, and heart failure. The standard treatment for PTTM not established. However, imatinib, a tyrosine kinase inhibitor of the PDGF receptor, may cause regression hypertension artery remodeling in PTTM. We report two cases who received an anti-PDGF agent imatinib developed during chemotherapy metastatic breast cancer. Case 1: 61-year-old woman underwent resection left...
Comprehensive cancer genomic profile (CGP) tests are being implemented under Japanese universal health insurance system. However, the clinical usefulness of CGP test for breast patients has not been evaluated. Of 310 who underwent testing at our institution between November 2019 and April 2021, 35 with metastatic whose treatment strategy was discussed by molecular tumor board within study period were investigated after exclusion 2 cases that could be analyzed. The turn-around time, drug...
This study aimed to estimate the medical costs associated with febrile neutropenia (FN) prophylaxis pegfilgrastim and evaluate its impact on survival outcomes in daily practice Japan. In this single-center retrospective study, we obtained data from 296 Japanese patients breast cancer receiving fluorouracil, epirubicin, cyclophosphamide (FEC)-100 chemotherapy; were divided into non-pegfilgrastim groups. We analyzed median of chemotherapy, drugs for all adverse events (AEs) FN, hospitalization...
Abstract Background Li-Fraumeni syndrome (LFS), a hereditary condition attributed to TP53 pathogenic variants,(PV), is associated with high risks for various malignant tumors, including breast cancer. Notably, individuals harboring PVs are more likely (67–83%) develop HER2 + cancer than noncarriers (16–25%). In this retrospective study, we evaluated the associations between variants and phenotype. Methods We conducted review of medical records patients LFS treated at single institution...
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, cancer-related, pulmonary complication that causes hypoxia and hypertension. We report on 42-year-old woman who was diagnosed with recurrent breast cancer detected due to the presence of PTTM. Eleven months after surgery for heterochronous bilateral left breast, she developed progressive dyspnea but computerized tomography showed no thromboembolism, transthoracic echocardiography revealed mild She PTTM by cytology from artery...
Combination chemotherapy with mitomycin C and methotrexate (MM) was reported to be effective for 24% of patients metastatic breast cancer (MBC) who had been treated anthracycline taxane. Antimetabolites such as capecitabine antitubulins vinorelbine have generally used MBC treatment after A subsequent choice should offered kept good performance status (PS) being aggressively anthracycline, taxane, capecitabine, (ATCV), but is not well clear which superior others ATCV. In this study, we...
Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Although eribulin well tolerated in heavily pretreated disease, eribulin-induced liver dysfunction (EILD) can occur, resulting treatment modification and subsequent poor disease control. We aimed to clarify the effect EILD on patient survival. The medical records 157 cancer treated between July 2011 November 2013 at Cancer Institute Hospital were retrospectively...